Skip to main content

CORRECTION article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1418274

Corrigendum: Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells

Provisionally accepted
Wei Huang Wei Huang 1*Y X Y X 2Fuxiang Ran Fuxiang Ran 2Zemei Ge Zemei Ge 2Runtao Li Runtao Li 2Jingrong Cui Jingrong Cui 2
  • 1 Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, China
  • 2 Peking University, Beijing, Beijing Municipality, China

This article is a correction to:

  1. Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells

    1. Read original article

The final, formatted version of the article will be published soon.

    Keywords: Proteasome inhibitor, YSY01A, STAT3 signaling, Protein degradation, Non-small cell lung carcinoma

    Received: 16 Apr 2024; Accepted: 03 Jul 2024.

    Copyright: © 2024 Huang, X, Ran, Ge, Li and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wei Huang, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.